Buy Recommendation for uniQure Driven by Promising AMT-260 Trial Results and Innovative LinQURE Technology

William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today.

Sami Corwin has given his Buy rating due to a combination of factors, primarily centered around the promising results from uniQure’s AMT-260 trial. The case study presented by uniQure demonstrated a significant reduction in seizure frequency for a patient with refractory mesial temporal lobe epilepsy, showing a 92% decrease in seizures without any serious adverse events. This outcome is particularly noteworthy as it aligns with similar positive data from Neurona Therapeutics’ cell therapy for the same condition.
Moreover, the use of uniQure’s LinQURE technology, which enables the delivery of multiple microRNAs with a single AAV vector, adds a layer of innovation and potential scalability to their approach. The absence of adverse neurological side effects, which are common with existing antiseizure medications, further enhances the attractiveness of AMT-260. As additional clinical data becomes available, there is potential for further validation of both AMT-260’s efficacy and the broader application of LinQURE technology, supporting the Buy recommendation.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.